Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (科济药业-B) shares rose over 4%, currently trading at 18.3 HKD with a transaction volume of 12.33 million HKD, following the announcement of an updated share buyback plan [1] Group 1: Share Buyback Plan - The company announced an updated share buyback plan, effective from November 13, 2025, allowing the repurchase of up to 25.461 million shares within 50 trading days in the open market [1] - The updated buyback plan's 25.461 million shares, combined with shares repurchased in 2025, will represent 5% of the total issued shares as of the authorization date in 2025 [1] Group 2: Shareholding Changes - The board was informed that Yijie Biotechnology Holdings Limited and its concert parties (collectively referred to as "Yijie Concert Group") purchased a total of 100,000 shares between November 6 and November 10, 2025 [1] - Following this acquisition, the Yijie Concert Group holds 218 million shares, accounting for approximately 37.92% of the total issued shares as of the announcement date, excluding treasury shares [1]

Group 1 - The core point of the article is that Kintor Pharmaceutical Co., Ltd. (02171) has announced an updated share repurchase plan, which will allow the company to buy back up to 25.461 million shares over a period of 50 trading days starting from November 13, 2025 [1] - The updated share repurchase plan represents approximately 5% of the total issued shares as of the date of the authorization in 2025 [1] - Following the announcement, Kintor's stock price increased by over 4%, reaching HKD 18.3 with a trading volume of HKD 12.33 million [1] Group 2 - The board of directors has been informed that Eucure Biopharma Co., Ltd. and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - After this acquisition, Eucure and its concert parties hold a total of 218 million shares, which accounts for approximately 37.92% of the total issued shares as of the announcement date, excluding treasury shares [1]

Policy Developments - The National Medical Insurance Administration announced that as of November 12, 2025, 24 provinces and regions in China have completed the deployment of the medical imaging cloud software, with 140 million indexed data uploaded to the national center [2] Drug and Device Approvals - Changchun High-tech's subsidiary received FDA approval for the clinical trial of GenSci143, a dual-specific antibody drug targeting B7-H3 and PSMA for treating advanced solid tumors [4] - Zai Lab announced that its ZG006 injection, in combination with etoposide and cisplatin, received clinical trial approval for advanced neuroendocrine carcinoma [5] - Heng Rui Medicine received approval for the clinical trial of Rivegromab tablets for prostate cancer [6] - Haisco announced that its HSK39297 tablets for age-related macular degeneration received clinical trial approval, showing promising preclinical results [7] Capital Market Activities - Kintor Pharmaceutical reported the repurchase of approximately 3.31 million shares since October 2025, with plans to repurchase up to 25.46 million shares over the next 50 trading days [9] - Changlian Co. signed an agreement to establish a joint venture with Shanghai Waigaoqiao Biopharmaceutical, contributing 30 million yuan for a 60% stake [10] Financial Reports - In the third quarter report, Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters of 2025, despite a revenue increase of 59.85% to 1.115 billion yuan, driven by sales of its core product [12] Industry Events - The first China-Africa Joint Medical Center was established in Guinea, aiming to enhance healthcare collaboration and address cardiovascular diseases in West Africa [14] Shareholder Actions - Renhe Pharmaceutical's controlling shareholder plans to reduce its stake by up to 0.21% through public trading or block transactions [16]

Performance Highlights - Tencent Holdings (00700.HK) reported Q3 revenue of 192.87 billion yuan, a year-on-year increase of 15% and a quarter-on-quarter increase of 5%. Net profit reached 63.13 billion yuan, up 19% year-on-year and 13% quarter-on-quarter [2] - Semiconductor Manufacturing International Corporation (00981.HK) achieved Q3 sales revenue of 2.38 billion USD, a quarter-on-quarter increase of 7.8% and a year-on-year increase of 9.7%. Gross margin improved to 22.0%, up 1.6 percentage points quarter-on-quarter [3] - JD Group (09618.HK) reported Q3 total revenue of 299.06 billion yuan, a year-on-year increase of 14.85%, while net profit decreased by 55.03% to 5.28 billion yuan [4] - JD Logistics (02618.HK) recorded Q3 revenue of 55.08 billion yuan, a year-on-year increase of 24.1%, with operating profit rising by 125.3% to 1.24 billion yuan [5] - Bilibili (09626.HK) achieved Q3 net revenue of 7.69 billion yuan (1.08 billion USD), a year-on-year increase of 5%, and turned a profit with a net profit of 469 million yuan (65.9 million USD) [6] Company News - Heng Rui Medicine (01276.HK) received clinical trial approval for its drug, with similar products expected to generate global sales of approximately 11.04 billion USD in 2024 [7] - China Pacific Insurance (02601.HK) reported that for the first ten months, life insurance premium income reached 241.32 billion yuan, a year-on-year increase of 9.9% [8] - Zhong An Online (06060.HK) reported total original insurance premium income of approximately 29.82 billion yuan for the first ten months, a year-on-year increase of 5.18% [9] Buyback Activities - Yongsheng Services (01995.HK) plans to repurchase up to approximately 173 million shares, accounting for about 10% of the issued share capital [12] - Kintor Pharmaceutical (02171.HK) intends to repurchase up to approximately 25.46 million shares [13] - China Feihe (06186.HK) spent 87.86 million HKD to repurchase 20 million shares at prices ranging from 4.37 to 4.40 HKD [14]

Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical-B (02171) by purchasing 50,000 shares at a price of HKD 17.2 per share, totaling HKD 860,000, raising his total holdings to approximately 218 million shares, which represents a 37.74% ownership [1]. Summary by Category Shareholding Activity - Guo Huaqing acquired 50,000 shares of Kintor Pharmaceutical-B at HKD 17.2 each, amounting to HKD 860,000 [1]. - Following this transaction, Guo's total shareholding in the company is about 218 million shares, equating to a 37.74% ownership stake [1].

Core Viewpoint - The non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical-B (02171) by purchasing 50,000 shares at a price of HKD 17.2 per share, totaling HKD 860,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Shareholding Activity** - Guo Huaqing acquired 50,000 shares of Kintor Pharmaceutical-B on November 12 [1] - The purchase price was HKD 17.2 per share, amounting to a total investment of HKD 860,000 [1] - Following this transaction, Guo's total shareholding in the company increased to approximately 218 million shares, representing a 37.74% ownership stake [1]

Core Viewpoint - The company has updated its share buyback plan, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be below its true value [1] Group 1: Share Buyback Plan - The updated share buyback plan allows the company to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025 [1] - The total shares to be repurchased, including those already bought back in 2025, will represent 5% of the total issued shares as of the authorization date [1] Group 2: Management Confidence - The board believes that the share buyback plan reflects the confidence of the directors and senior management in the company's long-term growth and market performance [1] - The board asserts that the buyback plan is in the best interest of the company and its shareholders [1] Group 3: Shareholder Activity - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this purchase, the concert group holds a total of 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) [1] - The board views this increase in shareholding as a sign of confidence from major shareholders regarding the company's prospects and growth potential [1]

Core Viewpoint - The company has updated its share buyback plan to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025, indicating confidence in its long-term growth and market performance [1] Group 1: Share Buyback Plan - The updated share buyback plan represents 5% of the total issued shares as of the authorization date in 2025 [1] - The board believes the current share price does not reflect the company's true value and business prospects [1] - The buyback plan is seen as being in the best interest of the company and its shareholders [1] Group 2: Shareholding Update - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this acquisition, the Yijie concert group holds 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) as of the announcement date [1]

Core Viewpoint - 科济药业-B (02171.HK) has announced an updated share repurchase plan, indicating a strategic move to enhance shareholder value through the buyback of shares [1] Group 1: Share Repurchase Details - Starting from November 13, 2025, the company plans to repurchase up to approximately 25.46 million shares within 50 trading days on the open market [1] - The total shares to be repurchased, including the approximately 3.31 million shares already bought back, will represent 5% of the total issued shares as of the authorization date for the 2025 share repurchase [1]

Group 1 - The company Kintor Pharmaceutical (02171) has updated its share buyback plan to repurchase up to 25,461,295 shares within 50 trading days starting from November 13, 2025 [1] - The updated buyback plan represents 5% of the total issued shares as of the authorization date in 2025, including shares already repurchased in 2025 [1] - The board believes that the current share price is below its true value and does not adequately reflect the company's business prospects, indicating confidence in long-term growth and market performance [1] Group 2 - The board has been informed that Eucure Biopharma and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this acquisition, Eucure and its concert parties hold a total of 218,048,730 shares, representing approximately 37.92% of the total issued shares as of the announcement date, excluding treasury shares [1]